S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
NASDAQ:FGEN

FibroGen (FGEN) Stock Forecast, Price & News

$0.89
+0.03 (+3.51%)
(As of 10:03 AM ET)
Compare
Today's Range
$0.86
$0.90
50-Day Range
$0.79
$2.09
52-Week Range
$0.70
$25.69
Volume
323,775 shs
Average Volume
2.46 million shs
Market Capitalization
$87.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

FibroGen MarketRank™ Forecast

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
2,390.4% Upside
$22.00 Price Target
Short Interest
Bearish
11.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$16,524 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.47) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

440th out of 969 stocks

Pharmaceutical Preparations Industry

197th out of 453 stocks


FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Price History

FGEN Stock News Headlines

Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
FibroGen stock plummets as muscular dystrophy drug trial fails
Stocks to Watch: FibroGen, Box
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
FibroGen Reports Second Quarter 2023 Financial Results
Expert Ratings for FibroGen
FibroGen Q2 2023 Earnings Preview
San FranciscoBusiness Times
FibroGen, Inc.: FibroGen Announces Leadership Transition
FibroGen Announces Leadership Transition
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings
8/07/2023
Today
10/02/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
592
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+2,449.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$-293,650,000.00
Net Margins
-246.75%
Pretax Margin
-248.26%

Debt

Sales & Book Value

Annual Sales
$140.73 million
Book Value
($0.02) per share

Miscellaneous

Free Float
95,863,000
Market Cap
$84.75 million
Optionable
Optionable
Beta
0.55
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Thane WettigMr. Thane Wettig (Age 58)
    Interim Chief Exec. Officer
    Comp: $807.35k
  • Mr. Juan Graham (Age 46)
    Sr. VP & CFO
    Comp: $991.76k
  • Dr. Elias Kouchakji (Age 67)
    Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
  • Ms. Christine L. Chung (Age 55)
    Sr. VP of China Operations
    Comp: $1.27M
  • Dr. Barry A. Berkowitz Ph.D.
    Founder
  • Dr. John J. Hunter Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Karen L. Bergman
    VP of Investor Relations & Corp. Communications
  • Mr. Michael D. Lowenstein J.D.
    Ph.D., Chief Legal Officer
  • Ms. Tricia Stewart
    Chief People Officer
  • Mr. Kirk A. Christoffersen MBA (Age 54)
    Chief Bus. Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2023?

6 Wall Street analysts have issued 1 year price objectives for FibroGen's stock. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they anticipate the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 2,449.5% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2023?

FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN stock has decreased by 94.6% and is now trading at $0.8629.
View the best growth stocks for 2023 here
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) announced its quarterly earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.07. The biopharmaceutical company had revenue of $44.32 million for the quarter, compared to analysts' expectations of $34.17 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 246.75%.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $0.86.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $84.75 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 592 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -